Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free BPCR Stock Alerts

BioPharma Credit (BPCR) Competitors

BioPharma Credit logo
GBX 0.96 -0.01 (-1.04%)
As of 12:01 PM Eastern
Compare

BPCR vs. LGT, RIV, SGEM, CBA, and NBMI

Should you buy BioPharma Credit stock or one of its competitors? MarketBeat compares BioPharma Credit with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioPharma Credit include Lighthouse Group (LGT), River and Mercantile Group (RIV), ScotGems (SGEM), Ceiba Investments (CBA), and NB Global Monthly Income Fund Ltd GBP (NBMI). These companies are all part of the "asset management" industry.

How does BioPharma Credit compare to Lighthouse Group?

Lighthouse Group (LON:LGT) and BioPharma Credit (LON:BPCR) are both small-cap asset management industry companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

27.0% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, BioPharma Credit had 1 more articles in the media than Lighthouse Group. MarketBeat recorded 1 mentions for BioPharma Credit and 0 mentions for Lighthouse Group. BioPharma Credit's average media sentiment score of 2.00 beat Lighthouse Group's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the news media.

Company Overall Sentiment
Lighthouse Group Neutral
BioPharma Credit Very Positive

BioPharma Credit has higher revenue and earnings than Lighthouse Group. Lighthouse Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lighthouse Group£53.42M0.00N/A£1.80N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.08

Lighthouse Group pays an annual dividend of GBX 0.01 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 732.2%. Lighthouse Group pays out 0.6% of its earnings in the form of a dividend. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

BioPharma Credit has a net margin of 92.62% compared to Lighthouse Group's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat Lighthouse Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Lighthouse GroupN/A N/A N/A
BioPharma Credit 92.62%11.29%4.98%

Summary

BioPharma Credit beats Lighthouse Group on 10 of the 12 factors compared between the two stocks.

How does BioPharma Credit compare to River and Mercantile Group?

BioPharma Credit (LON:BPCR) and River and Mercantile Group (LON:RIV) are both small-cap asset management industry companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 732.2%. River and Mercantile Group pays an annual dividend of GBX 0.09 per share. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. River and Mercantile Group pays out -4.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, BioPharma Credit had 1 more articles in the media than River and Mercantile Group. MarketBeat recorded 1 mentions for BioPharma Credit and 0 mentions for River and Mercantile Group. BioPharma Credit's average media sentiment score of 2.00 beat River and Mercantile Group's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.

Company Overall Sentiment
BioPharma Credit Very Positive
River and Mercantile Group Neutral

27.0% of BioPharma Credit shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioPharma Credit has higher revenue and earnings than River and Mercantile Group. River and Mercantile Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.08
River and Mercantile Group£74.82M0.00N/A-£2.20N/A

BioPharma Credit has a net margin of 92.62% compared to River and Mercantile Group's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat River and Mercantile Group's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
River and Mercantile Group N/A N/A N/A

Summary

BioPharma Credit beats River and Mercantile Group on 11 of the 12 factors compared between the two stocks.

How does BioPharma Credit compare to ScotGems?

BioPharma Credit (LON:BPCR) and ScotGems (LON:SGEM) are both small-cap asset management industry companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

BioPharma Credit has higher revenue and earnings than ScotGems. ScotGems is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.08
ScotGems£5.07M0.00N/A£0.07N/A

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 732.2%. ScotGems pays an annual dividend of GBX 4 per share. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. ScotGems pays out 5,714.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

27.0% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioPharma Credit has a net margin of 92.62% compared to ScotGems' net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat ScotGems' return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
ScotGems N/A N/A N/A

In the previous week, BioPharma Credit had 1 more articles in the media than ScotGems. MarketBeat recorded 1 mentions for BioPharma Credit and 0 mentions for ScotGems. BioPharma Credit's average media sentiment score of 2.00 beat ScotGems' score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.

Company Overall Sentiment
BioPharma Credit Very Positive
ScotGems Neutral

Summary

BioPharma Credit beats ScotGems on 11 of the 12 factors compared between the two stocks.

How does BioPharma Credit compare to Ceiba Investments?

BioPharma Credit (LON:BPCR) and Ceiba Investments (LON:CBA) are both small-cap financial services companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

BioPharma Credit has higher revenue and earnings than Ceiba Investments. Ceiba Investments is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.08
Ceiba Investments-£39.52M-1.01£8.64M-£30.00N/A

Ceiba Investments has a net margin of 6,890.36% compared to BioPharma Credit's net margin of 92.62%. BioPharma Credit's return on equity of 11.29% beat Ceiba Investments' return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
Ceiba Investments 6,890.36%-25.40%2.31%

BioPharma Credit has a beta of 0.22126153, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Ceiba Investments has a beta of 0.227, meaning that its stock price is 77% less volatile than the broader market.

27.0% of BioPharma Credit shares are owned by institutional investors. Comparatively, 1.4% of Ceiba Investments shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Comparatively, 47.7% of Ceiba Investments shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, BioPharma Credit had 1 more articles in the media than Ceiba Investments. MarketBeat recorded 1 mentions for BioPharma Credit and 0 mentions for Ceiba Investments. BioPharma Credit's average media sentiment score of 2.00 beat Ceiba Investments' score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.

Company Overall Sentiment
BioPharma Credit Very Positive
Ceiba Investments Neutral

Summary

BioPharma Credit beats Ceiba Investments on 10 of the 13 factors compared between the two stocks.

How does BioPharma Credit compare to NB Global Monthly Income Fund Ltd GBP?

BioPharma Credit (LON:BPCR) and NB Global Monthly Income Fund Ltd GBP (LON:NBMI) are both small-cap financial services companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

BioPharma Credit has higher revenue and earnings than NB Global Monthly Income Fund Ltd GBP. NB Global Monthly Income Fund Ltd GBP is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.08
NB Global Monthly Income Fund Ltd GBPN/AN/AN/A£0.17N/A

BioPharma Credit has a net margin of 92.62% compared to NB Global Monthly Income Fund Ltd GBP's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat NB Global Monthly Income Fund Ltd GBP's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
NB Global Monthly Income Fund Ltd GBP N/A N/A N/A

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 732.2%. NB Global Monthly Income Fund Ltd GBP pays an annual dividend of GBX 9 per share. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. NB Global Monthly Income Fund Ltd GBP pays out 5,294.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

27.0% of BioPharma Credit shares are held by institutional investors. Comparatively, 44.3% of NB Global Monthly Income Fund Ltd GBP shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by insiders. Comparatively, 0.2% of NB Global Monthly Income Fund Ltd GBP shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, BioPharma Credit had 1 more articles in the media than NB Global Monthly Income Fund Ltd GBP. MarketBeat recorded 1 mentions for BioPharma Credit and 0 mentions for NB Global Monthly Income Fund Ltd GBP. BioPharma Credit's average media sentiment score of 2.00 beat NB Global Monthly Income Fund Ltd GBP's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.

Company Overall Sentiment
BioPharma Credit Very Positive
NB Global Monthly Income Fund Ltd GBP Neutral

Summary

BioPharma Credit beats NB Global Monthly Income Fund Ltd GBP on 9 of the 12 factors compared between the two stocks.

Get BioPharma Credit News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPCR vs. The Competition

Export
MetricBioPharma CreditAsset Management IndustryFinancial SectorLON Exchange
Market Cap£10.75M£2.45B£5.75B£2.78B
Dividend Yield7.29%6.02%5.28%6.12%
P/E Ratio0.0825.8216.34364.34
Price / Sales0.082,112.761,113.6187,480.01
Price / Cash1.1960.1591.3227.85
Price / Book0.011.386.507.74
Net Income£10.42B£264.62M£1.14B£5.89B
7 Day Performance-1.04%-0.12%0.31%0.21%
1 Month PerformanceN/A-30.82%-7.23%N/A
1 Year Performance9.13%11.37%19.72%74.70%

BioPharma Credit Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPCR
BioPharma Credit
N/AGBX 0.96
-1.0%		N/A+9.8%£10.75M£132.06M0.08N/A
LGT
Lighthouse Group
N/AN/AN/AN/A£42.46M£53.42M18.47156
RIV
River and Mercantile Group
N/AN/AN/AN/A£42.40M£74.82MN/A300
SGEM
ScotGems
N/AN/AN/AN/A£42.02M£5.07M1,121.43N/A
CBA
Ceiba Investments
N/AGBX 30
+3.4%		N/AN/A£41.30M-£39.52MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BPCR) was last updated on 6/4/2026 by MarketBeat.com Staff.
From Our Partners
How to claim a stake in SpaceX before the June 12 IPO
SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...
Brownstone Research | Sponsoredtc pixel
Trump’s secret China deal
Trump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...
Porter & Company | Sponsoredtc pixel
June 4: The day smart money moves (not June 12)
Everyone is watching June 12 - the SpaceX listing date. The real deadline is June 4, when Goldman Sachs, Morga...
Behind the Markets | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
AI breakthrough hidden inside SpaceX exposed on June 11
On June 11, SpaceX is hosting a major investor event - and growth investor Louis Navellier believes Elon Musk ...
InvestorPlace | Sponsoredtc pixel
Important SpaceX PREDICTION from Trading Legend Jon Najarian
Trading legend Jon Najarian says the real story behind the projected June 12 SpaceX IPO isn't the IPO itself -...
Banyan Hill Publishing | Sponsoredtc pixel
Research Firm that Warned of Dot-Com Crash Says: “These 7 Stocks Could Fall 50% or More”
Alexander Green, Chief Investment Strategist at The Oxford Club, issued a warning before the Dot-Com Crash of ...
The Oxford Club | Sponsoredtc pixel